MAIA Biotechnology Files 8-K: Material Agreement, Equity Sales
Ticker: MAIA · Form: 8-K · Filed: Mar 26, 2024 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | 8-K |
| Filed Date | Mar 26, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $2, $1.33 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, equity-sale, filing
TL;DR
MAIA Bio inked a material deal, sold some stock, and filed financials. Big moves ahead.
AI Summary
MAIA Biotechnology, Inc. announced on March 25, 2024, that it entered into a Material Definitive Agreement. The company also reported on unregistered sales of equity securities and other events. The filing includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate activity for MAIA Biotechnology, including a new material agreement and equity transactions, which could impact its financial standing and future operations.
Risk Assessment
Risk Level: medium — The filing details a material definitive agreement and unregistered equity sales, which can introduce financial and regulatory risks.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — Registrant
- March 25, 2024 (date) — Date of earliest event reported
- 444 West Lake Street, Suite 1700 Chicago, IL 60606 (address) — Principal executive offices
FAQ
What is the nature of the Material Definitive Agreement entered into by MAIA Biotechnology?
The filing does not specify the details of the Material Definitive Agreement, only that one was entered into on March 25, 2024.
What type of equity securities were sold under the unregistered sales?
The filing mentions unregistered sales of equity securities but does not provide specific details about the type or amount of securities sold.
Are there any financial statements included in this filing?
Yes, the filing indicates that financial statements and exhibits are included.
What is MAIA Biotechnology's principal executive office address?
MAIA Biotechnology's principal executive offices are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.
What is the filing date for this 8-K report?
This 8-K report was filed as of March 26, 2024, with the earliest event reported on March 25, 2024.
Filing Stats: 956 words · 4 min read · ~3 pages · Grade level 11.5 · Accepted 2024-03-26 15:36:34
Key Financial Figures
- $0.0001 — f the Company's common stock, par value $0.0001 per share (" Common Stock "), and (ii)
- $2 — f Common Stock, at a price per share of $2.295, for an aggregate purchase price of
- $1.33 million — gregate purchase price of approximately $1.33 million. The Shares and the Warrants (and the
Filing Documents
- d776139d8k.htm (8-K) — 29KB
- d776139dex41.htm (EX-4.1) — 82KB
- d776139dex101.htm (EX-10.1) — 321KB
- d776139dex991.htm (EX-99.1) — 9KB
- 0001193125-24-077564.txt ( ) — 686KB
- maia-20240325.xsd (EX-101.SCH) — 3KB
- maia-20240325_lab.xml (EX-101.LAB) — 18KB
- maia-20240325_pre.xml (EX-101.PRE) — 11KB
- d776139d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: March 26, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer 4